uracil has been researched along with Adverse Drug Event in 17 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 9.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 8.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 7.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 7.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 7.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| " However, ribavirin is associated with adverse events that can limit its use." | 6.90 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. ( Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K, 2019) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 5.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| "Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age." | 5.27 | Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. ( Cohen, SJ; Grothey, A; Hochster, HS; Makris, L; Mayer, RJ; Winkler, R, 2018) |
| "Trifluridine/tipiracil (TAS-102) has achieved modest efficacy in the late-line treatment of metastatic colorectal cancer." | 4.31 | An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study. ( Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J, 2023) |
| "Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC)." | 3.96 | Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram. ( Candamio Folgar, S; Carmona Campos, M; Cousillas Castiñeiras, A; Covela Rúa, M; de la Cámara Gómez, J; Fernandez Montes, A; Gallardo Martín, E; García Gómez, J; Gonzalez Villarroel, P; Jorge Fernández, M; Martinez Lago, N; Méndez Méndez, JC; París Bouzas, L; Pellón Augusto, ML; Reboredo López, M; Salgado Fernández, M; Vazquez Rivera, F, 2020) |
| "Regorafenib and TAS-102 are novel antitumor agents for patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard therapies." | 3.83 | Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. ( Doki, Y; Haraguchi, N; Hata, T; Hayashi, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Sueda, T; Sugiura, T; Takahashi, H, 2016) |
| "Overall health-related quality of life did not deteriorate during adjuvant chemotherapy with oral uracil/tegafur plus leucovorin in patients with colorectal cancer, despite the effect from surgical damage, whereas the development of Grade 3 toxicities negatively affected on short-term health-related quality of life." | 3.76 | Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010) |
| " However, ribavirin is associated with adverse events that can limit its use." | 2.90 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. ( Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K, 2019) |
| "Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | 2.82 | A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
| " The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported." | 2.55 | Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. ( Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H, 2017) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| "Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment." | 1.40 | Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Nie, C | 1 |
| Xu, W | 1 |
| Chen, B | 1 |
| Lv, H | 1 |
| Wang, J | 1 |
| Liu, Y | 1 |
| He, Y | 1 |
| Wang, S | 1 |
| Zhao, J | 1 |
| Chen, X | 1 |
| Meulendijks, D | 1 |
| Henricks, LM | 1 |
| Jacobs, BAW | 1 |
| Aliev, A | 1 |
| Deenen, MJ | 1 |
| de Vries, N | 1 |
| Rosing, H | 1 |
| van Werkhoven, E | 1 |
| de Boer, A | 1 |
| Beijnen, JH | 1 |
| Mandigers, CMPW | 1 |
| Soesan, M | 1 |
| Cats, A | 1 |
| Schellens, JHM | 1 |
| Poordad, F | 2 |
| Nelson, DR | 2 |
| Feld, JJ | 1 |
| Fried, MW | 1 |
| Wedemeyer, H | 1 |
| Larsen, L | 1 |
| Cohen, DE | 1 |
| Cohen, E | 1 |
| Mobashery, N | 1 |
| Tatsch, F | 1 |
| Foster, GR | 1 |
| González-Colominas, E | 1 |
| Londoño, MC | 1 |
| Morillas, RM | 1 |
| Torras, X | 1 |
| Mojal, S | 1 |
| Lens, S | 1 |
| López, D | 1 |
| Gallego, A | 1 |
| Mariño, Z | 1 |
| Ardèvol, M | 1 |
| Pagès, N | 1 |
| Solà, R | 1 |
| Carrión, JA | 1 |
| Mayer, RJ | 1 |
| Hochster, HS | 1 |
| Cohen, SJ | 1 |
| Winkler, R | 1 |
| Makris, L | 1 |
| Grothey, A | 1 |
| Sedghi, S | 1 |
| Pockros, PJ | 1 |
| Ravendhran, N | 1 |
| Reindollar, R | 1 |
| Lucey, MR | 1 |
| Epstein, M | 1 |
| Bank, L | 1 |
| Bernstein, D | 1 |
| Trinh, R | 1 |
| Krishnan, P | 1 |
| Polepally, AR | 1 |
| Unnebrink, K | 1 |
| Martinez, M | 1 |
| Fernandez Montes, A | 1 |
| Vazquez Rivera, F | 1 |
| Martinez Lago, N | 1 |
| Covela Rúa, M | 1 |
| Cousillas Castiñeiras, A | 1 |
| Gonzalez Villarroel, P | 1 |
| de la Cámara Gómez, J | 1 |
| Méndez Méndez, JC | 1 |
| Salgado Fernández, M | 1 |
| Candamio Folgar, S | 1 |
| Reboredo López, M | 1 |
| Carmona Campos, M | 1 |
| Gallardo Martín, E | 1 |
| Jorge Fernández, M | 1 |
| Pellón Augusto, ML | 1 |
| París Bouzas, L | 1 |
| García Gómez, J | 1 |
| Nakamura, Y | 1 |
| Inagaki, M | 1 |
| Shimizu, T | 1 |
| Fujita, K | 1 |
| Inoue, M | 1 |
| Gotoh, H | 1 |
| Oguchi, K | 1 |
| Goto, Y | 1 |
| Liu, P | 1 |
| Wu, C | 1 |
| Song, W | 1 |
| Yu, L | 1 |
| Yang, X | 1 |
| Xiang, R | 1 |
| Wang, F | 1 |
| Yang, J | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Wettergren, Y | 1 |
| Oki, E | 1 |
| Murata, A | 1 |
| Yoshida, K | 1 |
| Maeda, K | 1 |
| Ikejiri, K | 1 |
| Munemoto, Y | 1 |
| Sasaki, K | 1 |
| Matsuda, C | 1 |
| Kotake, M | 1 |
| Suenaga, T | 1 |
| Matsuda, H | 1 |
| Emi, Y | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Hamada, C | 1 |
| Saji, S | 1 |
| Maehara, Y | 1 |
| Sueda, T | 1 |
| Sakai, D | 1 |
| Kudo, T | 1 |
| Sugiura, T | 1 |
| Takahashi, H | 1 |
| Haraguchi, N | 1 |
| Nishimura, J | 1 |
| Hata, T | 1 |
| Hayashi, T | 1 |
| Mizushima, T | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Satoh, T | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 1 |
| Watanabe, M | 1 |
| Matsui, N | 1 |
| Tsunoda, Y | 1 |
| Hatano, K | 1 |
| Nonomura, N | 1 |
| Nishimura, K | 1 |
| Kawashima, A | 1 |
| Mukai, M | 1 |
| Nagahara, A | 1 |
| Nakai, Y | 1 |
| Nakayama, M | 1 |
| Takayama, H | 1 |
| Tsujimura, A | 1 |
| Okuyama, A | 1 |
| LEMON, HM | 1 |
| Remaud, G | 1 |
| Boisdron-Celle, M | 1 |
| Hameline, C | 1 |
| Morel, A | 1 |
| Gamelin, E | 1 |
| Palleschi, M | 1 |
| Palleschi, A | 1 |
| D'Amore, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy[NCT02286492] | 0 participants | Expanded Access | Approved for marketing | ||||
| An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)[NCT02609659] | Phase 3 | 105 participants (Actual) | Interventional | 2015-10-28 | Completed | ||
| Clinical and Imaging Biomarker Trial of Uridine for Veterans With Suicidal Ideation[NCT03265964] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-04-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants with hemoglobin <10 g/dL during treatment is provided. (NCT02609659)
Timeframe: up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA + RBV 600 mg | 0 |
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA < LLOQ during treatment; confirmed increase of > 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment. (NCT02609659)
Timeframe: Up to 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA + RBV 600 mg | 1.0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels < LLOQ at the end of treatment. (NCT02609659)
Timeframe: From the end of treatment through 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA + RBV 600 mg | 4.1 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification [
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA + RBV 600 mg | 89.5 |
The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided. (NCT02609659)
Timeframe: Baseline (Day 1) to Weeks 2, 4, 8, and 12, and the Final Treatment Visit (up to 12 weeks)
| Intervention | g/L (Mean) | ||||
|---|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | Final Treatment Visit | |
| 3-DAA + RBV 600 mg | -6.4 | -8.9 | -11.2 | -12.4 | -12.1 |
2 reviews available for uracil and Adverse Drug Event
| Article | Year |
|---|---|
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; C | 2017 |
[Drug induced cytopenias].
Topics: Agranulocytosis; Aminopyrine; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antihypertensive Agen | 1967 |
4 trials available for uracil and Adverse Drug Event
| Article | Year |
|---|---|
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Respon | 2018 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule | 2019 |
Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug-Related Side Effect | 2013 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
11 other studies available for uracil and Adverse Drug Event
| Article | Year |
|---|---|
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interacti | 2018 |
Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects a | 2020 |
Uridine decreases morphine-induced behavioral sensitization by decreasing dorsal striatal dopamine release possibly via agonistic effects at GABAA receptors.
Topics: Analgesics, Opioid; Animals; Animals, Inbred Strains; beta-Alanine; Bicuculline; Corpus Striatum; Di | 2014 |
Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; | 2014 |
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Drug | 2016 |
Health-related quality of life in patients with colorectal cancer who receive oral uracil and tegafur plus leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined | 2010 |
Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combi | 2011 |
Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.
Topics: Administration, Intravenous; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Glucose; | 1960 |
An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.
Topics: Chromatography, High Pressure Liquid; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; | 2005 |